• Agios won European Commission marketing authorization for PYRUKYND (mitapivat) to treat anemia in adults with transfusion-dependent or non-transfusion-dependent alpha- or beta-thalassemia across the EU.
• The decision expands mitapivat’s thalassemia label to a fourth major market, following prior clearances in the U.S., Saudi Arabia, and the United Arab Emirates.
• Avanzanite Bioscience will continue to distribute and commercialize PYRUKYND in Europe under an exclusive agreement covering the European Economic Area, the UK, and Switzerland.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605220915PRIMZONEFULLFEED9725348) on May 22, 2026, and is solely responsible for the information contained therein.